started · updated
Access to advanced therapies remains a challenge for patients in Poland
While medical advancements have increased therapeutic options for myasthenia gravis, patients in Poland face significant barriers to accessing these treatments. Sylwia Łukomska, president of the Myasthenia Gravis Face to Face Association, notes that although the B. 157 drug program has expanded to include three modern therapies as of July 2024, many severely ill patients remain unable to benefit.
Key obstacles include financial constraints, an insufficient number of medical centers authorized to implement the drug program, and overly restrictive qualification criteria. The association is actively participating in reimbursement processes and engaging with the Agency for Health Technology Assessment and Tariffication to advocate for broader patient access.
Entities
Agency for Health Technology Assessment and Tariffication · Myasthenia Gravis Face to Face Association · Poland · Sylwia Łukomska